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Background: Opioid-based postsurgical analgesia exposes patients undergoing laparoscopic colectomy to
elevated risk for gastrointestinal motility problems and other opioid-related adverse events (ORAEs). TheKey Words:
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purpose of our research was to investigate postsurgical outcomes, including opioid consumption, hospital
length of stay, and ORAE risk associated with a multimodal analgesia regimen, employing a single
administration of liposome bupivacaine as well as other analgesics that act by different mechanisms.
Methods: We analyzed combined results from 6 Phase IV, prospective, single-center studies in which
patients undergoing laparoscopic colectomy received opioid-based intravenous patient-controlled analge-
sia (PCA) or multimodal analgesia incorporating intraoperative administration of liposome bupivacaine.
As-needed rescue therapy was available to all patients. Primary outcome measures were postsurgical
opioid consumption, hospital length of stay, and hospitalization costs. Secondary measures included time
to ﬁrst rescue opioid use, patient satisfaction with analgesia (assessed using a 5-point Likert scale),
and ORAEs.
Results: Eighty-two patients underwent laparoscopic colectomy and did not meet intraoperative exclusion
criteria (PCA n ¼ 56; multimodal analgesia n ¼ 26). Compared with the PCA group, the multimodal
analgesia group had signiﬁcantly lower mean total postsurgical opioid consumption (96 vs 32 mg,
respectively; P o 0.0001) and shorter median postsurgical hospital length of stay (3.0 vs 4.0 days; P ¼
0.0019). Geometric mean costs were $11,234 and $13,018 in the multimodal analgesia and PCA groups,
respectively (P ¼ 0.2612). Median time to ﬁrst rescue opioid use was longer in the multimodal analgesia
group versus PCA group (1.1 hours vs 0.6 hours, respectively; P¼0.0003). ORAEs were experienced by 41%
of patients receiving intravenous opioid PCA and 8% of patients receiving multimodal analgesia (P ¼
0.0019). Study limitations included use of an open-label, nonrandomized design; small population size;
and the inability to isolate treatment-related effects speciﬁcally attributable to liposome bupivacaine.
Conclusions: Compared with intravenous opioid PCA, a liposome bupivacaine-based multimodal analgesia
regimen reduced postsurgical opioid use, hospital length of stay, and ORAEs, and may lead to improved
postsurgical outcomes following laparoscopic colectomy.
& 2013. The Authors. Published by Elsevier Inc. All rights reserved.Published by Elsevier Inc. All right
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As a result of their demonstrated efﬁcacy, opioid analgesics
continue to be the foundation for most postsurgical pain manage-
ment regimens; however, opioid-related adverse events (ORAEs)
exact a high toll in morbidity, hospital length of stay (LOS), ands reserved.
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gery appear to be especially vulnerable to exacerbation of GI motility
problems (postoperative ileus and small bowel obstruction).2,3
The management of postsurgical pain has been the focus of
increasing attention during the past 3 decades; consensus recom-
mendations for more effective postsurgical analgesia have been
developed and published by government, regulatory, and medical
organizations.4–7 Despite these efforts, improvement in reducing
the incidence and severity of postsurgical pain has been slow.
Patient surveys conducted during the past 2 decades have failed to
demonstrate improvement over time, consistently reporting high
incidences of postoperative pain (475% of surgical patients), with
most affected patients describing their pain as moderate, severe,
or extreme.8–10
The application of laparoscopic techniques in colectomy proce-
dures has helped reduce postsurgical morbidity, pain severity,
and LOS, although postsurgical pain remains a signiﬁcant driver
of prolonged recovery time.11 In the context of laparoscopic
colectomy, multimodal analgesia has been shown to reduce post-
surgical opioid use, pain, time to resumption of a normal diet,
and LOS, in comparison with conventional intravenous (IV) opioid-
based patient-controlled analgesia (PCA).12–14 Moreover, guide-
lines issued by the American Society of Anesthesiologists
strongly endorse the use of multimodal analgesia in the perioper-
ative setting whenever possible.4 Multimodal analgesic techni-
ques involve the use of 2 or more analgesic drugs that act by
different mechanisms delivered by the same or different routes
of administration to improve pain control and minimize
ORAEs.4,15
Liposome bupivacaine is a long-acting liposomal formulation
of bupivacaine indicated for injection into the surgical site to
produce postsurgical analgesia. In clinical studies involving a range
of different surgical settings, liposome bupivacaine has been
well tolerated and shown to provide postsurgical analgesia for
up to 72 hours, extend the time to ﬁrst opioid use, and reduce
postsurgical opioid consumption and incidence of ORAEs when
administered as a key component of multimodal analgesic regi-
mens.16–19
There are no previous reports from studies of liposome bupiva-
caine in patients undergoing minimally invasive GI surgery.
This article reports combined results from studies of liposome
bupivacaine (collectively known as Extended PaIn Relief Trial
Utilizing the Inﬁltration of a Long-Acting Multivesicular LiPo-
some FoRmulation Of BupiVacaine, Exparel [IMPROVE]) in adults
undergoing laparoscopic colectomy under general anesthesia. TheRectus abdominis Linea alba
Fig. 1. (A) Front view of inﬁltration path for administration of liposome bupivacain
administered on each side of the surgical site following the paths shown. (B) Axial view
depth of liposome bupivacaine administration. Reprinted with permission from Best
PocketGuide. Copyright © 2012 International Guidelines Center. www.GuidelineCentralobjective of our analysis was to compare total opioid burden and
health economic outcomes for patients who received liposome
bupivacaine-based multimodal analgesia versus those who received
a conventional IV opioid PCA regimen for postsurgical pain follow-
ing laparoscopic colectomy.Patients and Methods
Results from 6 single-center studies, later amended to 2 multi-
center studies, were combined and analyzed. Combined analysis of
data from the individual studies was prespeciﬁed in study proto-
cols, and was performed to improve statistical power to detect
differences in outcomes between the treatment groups. These
were Phase IV, prospective, multicenter, open-label, sequential-
cohort studies designed to evaluate opioid burden and health
economic outcomes associated with a multimodal analgesia regi-
men incorporating intraoperatively administered liposome bupi-
vacaine 266 mg compared with standard of care (postsurgical PCA)
using IV morphine or hydromorphone (IV opioid PCA).
All study protocols were approved by the institutional review
boards of the participating institutions and the studies were
conducted in accordance with International Conference on Har-
monisation Guideline for Good Clinical Practice and/or US Food
and Drug Administration Title 21 Code of Federal Regulations Part
56. All patients provided written informed consent before
participation.
Patients were eligible for study inclusion if they were aged 18
years or older and were scheduled to undergo laparoscopic
segmental colectomy with a primary anastomosis. Key exclusion
criteria included pregnancy or unwillingness to use acceptable
birth control; a history of drug or alcohol abuse; severe hepatic
impairment; any concomitant condition that, in the opinion of the
investigator, could preclude study participation; any concomitant
surgical procedure(s) or unplanned changes in surgery (eg, multi-
ple segmental resections, conversion from laparoscopic to open
colectomy); or treatment with intraoperative opioids (other than
fentanyl), nonsteroidal anti-inﬂammatory drugs, local anesthetics
(other than liposome bupivacaine), or alvimopan.
Apart from the difference in surgical model and the multicenter
nature of these studies, the study protocols were similar to that
employed by Cohen20 in a single-center study of patients under-
going open colectomy. Sequential cohorts (IV opioid PCA cohort
followed by liposome bupivacaine-based multimodal analgesiaRectus
abdominis
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tissue
Dermis
Linea alba
Suture
e into subcutaneous and dermal regions. About 4 mL study drug solution was
of inﬁltration depth into subcutaneous and dermal regions. The dotted line shows
Inﬁltration Practices: Local Analgesic Inﬁltration Techniques for Abdominal Surgery
.com. All rights reserved.21
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Fig. 2. (A) Front view of inﬁltration path for administration of liposome bupivacaine into perifascial regions. About 1 mL study drug solution was administered to deep tissue
on each side of the surgical site following the paths shown. (B) Axial view of inﬁltration depth into perifascial (deep tissue) regions. The dotted line shows depth of liposome
bupivacaine administration. Reprinted with permission from Best Inﬁltration Practices: Local Analgesic Inﬁltration Techniques for Abdominal Surgery PocketGuide. Copyright ©
2012 International Guidelines Center. www.GuidelineCentral.com. All rights reserved.21
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ing procedures within 2 weeks of the planned surgery.
Study treatment of patients in the IV opioid PCA cohort was
initiated as soon as possible after surgery on Study Day 1 (ie, day of
surgery). Patients in the liposome bupivacaine-based multimodal
analgesia cohort received a single dose of liposome bupivacaine
(266 mg in 40 mL 0.9% normal saline) administered using a
moving-needle technique before wound closure. A 30-mL aliquot
of liposome bupivacaine was divided into 2 15-mL aliquots for equal
administration into the left and right sides of the surgical site; from
these aliquots, approximately 25% was infused into the junction
between the subcutaneous and dermal regions (Figure 1)21 and 75%
was infused into the perifascial region (Figure 2).21 The remaining
10 mL was divided across the trocar sites, using a 75%/25% split for
the perifascial region and the subcutaneous-dermal junction region,
respectively (Figure 3).21 Patients in the liposome bupivacaine-based
multimodal analgesia group also received IV ketorolac 30 mg (or
nonsteroidal anti-inﬂammatory drug equivalent) at the end of
surgery, followed by IV or oral acetaminophen 1000 mg given every
6 hours and oral ibuprofen 600 mg every 6 hours (starting when oral
therapy was ﬁrst tolerated), for 72 hours after surgery or until
hospital discharge, whichever came ﬁrst. All patients in both treat-
ment arms were offered rescue therapy with IV opioid and/or oral
opioid/acetaminophen combination on an as-needed basis (acetami-
nophen use was limited to 4000 mg/d). Other facets of perioperative
management were carried out according to the standard of care at
each individual study site.
Postsurgically, IV opioid PCA was continued in the IV opioid
PCA group and as-needed rescue analgesics were continued inLaparoscope
Epigastric
vessels
Fig. 3. (A) Front view of anticipated trocar sites. About 10 mL study drug solution was
trocar placement. (B) Axial view of liposome bupivacaine inﬁltration into the trocar tract.
Techniques for Abdominal Surgery PocketGuide. Copyright © 2012 International Guidelinboth treatment groups until hospital discharge, with cumulative
opioid use and adverse events (AEs) recorded through the earlier
of Day 30 or discharge. AEs were assessed through Study Day 30,
and patient questionnaires were administered on Day 30 to assess
postsurgical complications and overall satisfaction with postsur-
gical analgesia.
The primary efﬁcacy outcome measures included total amount
of opioids consumed after surgery, total hospitalization cost, and
postsurgical LOS (time between wound closure and discharge or
Day 30, whichever came ﬁrst). Secondary outcome measures
included postsurgical incidence of ORAEs (eg, somnolence, respi-
ratory depression, hypoventilation, hypoxia, dry mouth, nausea,
vomiting, constipation, sedation, confusion, pruritus, urinary
retention, or postoperative ileus) and AEs through Day 30; patient
overall satisfaction with postsurgical analgesia assessed on Day 30
using a 5-point Likert scale (patient response options included
“extremely satisﬁed,” “satisﬁed,” “neither satisﬁed nor dissatis-
ﬁed,” “dissatisﬁed,” and “extremely dissatisﬁed”); and patient
responses to a follow-up survey on Day 30 regarding hospital
readmission, unplanned medical visits, health-related problems,
and contact with health care providers.
The safety population included all patients who underwent the
planned surgery. The efﬁcacy population included all patients who
underwent laparoscopic colectomy as planned and who did not
meet any of the intraoperative exclusion criteria. A 1-way ANOVA
model after a natural logarithm transformation was used for
between-group comparisons of continuous efﬁcacy measures (eg,
amount of opioids consumed and total hospitalization costs); all
opioid consumption amounts were converted to morphinePeritoneum Preperitoneal
space
Posterior
abdominal
fascia
Anterior
abdominal
fascia
divided and administered across trocar sites. The dotted arrows show locations for
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Table I
Patient demographics and selected baseline characteristics.*
Characteristic
IV opioid PCA
regimen (n ¼ 56)
Liposome bupivacaine-based
multimodal regimen (n ¼ 26)
Age, y 59 (15) 55 (10)
Sex
Male 28 (50) 12 (46)
Female 28 (50) 14 (54)
Race
White 45 (80) 23 (89)
Black 7 (13) 2 (8)
Asian 1 (2) 1 (4)
Other 3 (5) 0
Body mass index 28.9 (7.0) 26.6 (5.4)
ASA physical status
classiﬁcation
1 1 (2) 0
2 27 (48) 19 (73)
3 26 (46) 7 (27)
4 2 (4) 0
ASA ¼ American Society of Anesthesiologists; IV ¼ intravenous; PCA ¼ patient-
controlled analgesia.
nValues for age and body mass index are given as mean (SD). Values for sex,
race, and ASA physical status classiﬁcation are given as n (%).
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total hospitalization costs, a common metric for reporting cost
data,22,23 were calculated by taking the nth root of the product of
total hospitalization costs for the patients in each treatment group,
where n ¼ the number of patients in the treatment group. For
categorical measures, between-group comparisons were conducted
using Fisher’s exact test. Kaplan-Meier analysis with a log-rank test
was used for comparison of LOS and time to ﬁrst postsurgical opioid
use. Signiﬁcance tests were 2-sided and based on a signiﬁcance
level of 0.05; no adjustments were made for multiple tests.Results
A total of 105 patients underwent the planned laparoscopic
colectomy; 82 received study treatment as prescribed in the study
protocols (56 in the IV opioid PCA group and 26 in the liposome
bupivacaine-based multimodal analgesia group). Patient demo-
graphics and baseline characteristics are summarized in Table I.
The IV opioid PCA group was, on average, slightly older, had a
higher proportion of black patients, a lower proportion of white
patients, and had more patients with comorbidities (based on
American Society of Anesthesiologists classiﬁcation) than the
multimodal analgesia group.
The mean (SD) total amount of postsurgical opioid consump-
tion was 32 (53) mg in the liposome bupivacaine-based multi-
modal analgesia group, compared with 96 (78) mg in the IV opioidTable II
Summary of results for secondary outcome measures.*
Result
IV
Time to ﬁrst opioid use, h 0
Proportion of patients who reported being extremely satisﬁed with their
postsurgical pain treatment 5
Proportion of patients who made unplanned visits with a health care provider after
surgery 1
Proportion of patients who made contact with a health care provider to discuss
recovery after surgery 1
IV ¼ intravenous; PCA ¼ patient-controlled analgesia.
nValues for time to ﬁrst opiod use given as median (range). Other values are givenPCA group (P o 0.0001). The median (range) postsurgical LOS was
3.0 (1.9–10.7) days in the multimodal analgesia group compared
with 4.0 (0–30.0) days in the IV opioid PCA group (P ¼ 0.0019).
The geometric mean total hospitalization cost was $11,234 in the
multimodal analgesia group compared with $13,018 in the IV
opioid PCA group (P ¼ 0.2612).
Results for the secondary efﬁcacy measures are summarized in
Table II. The time to ﬁrst opioid use was signiﬁcantly longer in the
liposome bupivacaine-based multimodal analgesia group than in
the IV opioid PCA group (median ¼ 1.1 vs 0.6 hours, respectively;
P ¼ 0.0003). Although results for the remaining outcomes favored
the multimodal analgesia group (higher proportion of patients
extremely satisﬁed with analgesia, lower proportion of patients
who reported unplanned visits to or contact with health care
providers), between-group differences for these measures did not
reach statistical signiﬁcance.
Adverse events are summarized in Table III. Overall, the most
frequently reported AEs were nausea (25%), abdominal pain (7%),
headache (7%), and anemia (6%). In the IV opioid PCA group, 17
patients (25%) experienced AEs that were considered by the
investigator to be related to the study drug; there were no reports
of AEs related to the study drug in the liposome bupivacaine-based
multimodal analgesia group. In the IV opioid PCA group, 9 patients
(13%) experienced a total of 14 serious AEs; in the multimodal
analgesia group, 5 patients (13%) experienced 15 serious AEs.
ORAEs, summarized based on the efﬁcacy population, are
shown in Table IV. One or more ORAEs were experienced by 23
patients (41%) in the IV opioid PCA group compared with 2 patients
(8%) in the liposome bupivacaine-based multimodal analgesia
group (P ¼ 0.0019). Fewer patients in the multimodal analgesia
group experienced ORAEs of nausea than in the IV opioid PCA
group (8% vs 30%, respectively; P ¼ 0.0261); there were no other
ORAEs reported in the multimodal analgesia group. The mean (SD)
number of ORAEs reported per patient was 0.6 (0.8) in the IV
opioid PCA group and 0.1 (0.3) in the multimodal analgesia group
(P ¼ 0.0020).Discussion
The IMPROVE series of studies has evaluated the inﬂuence of an
opioid-sparing liposome bupivacaine-based multimodal analgesic
regimen compared with IV opioid-based PCA on clinical and health
economic outcomes in patients undergoing GI surgery. The
IMPROVE studies have addressed 3 GI surgery models (ie, open
colectomy, laparoscopic colectomy, and ileostomy reversal) in both
single- and multi-institutional settings. In a previously published
IMPROVE study report,20 patients undergoing open colectomy
treated with a liposome bupivacaine-based multimodal regimen
were shown to have signiﬁcantly reduced postsurgical opioidopioid PCA regimen
(n ¼ 56)
Liposome bupivacaine-based multimodal
regimen (n ¼ 26) P
.6 (0, 21) 1.1 (0.2, 119) 0.0003
4 65 0.278
6 4 0.156
3 8 0.711
as %.
Table III
Summary of adverse events occurring in Z5% of patients in any treatment group
(safety population).*
Adverse event
IV opioid PCA
regimen (n ¼ 67)
Liposome bupivacaine-based
multimodal regimen (n ¼ 38)
Patients with any
adverse event
53 (79) 15 (40)
Nausea 23 (34) 3 (8)
Abdominal pain 5 (8) 2 (5)
Headache 7 (10) 0
Anemia 4 (6) 2 (5)
Abdominal
distension
5 (8) 0
Pruritus 5 (8) 0
Urinary retention 5 (8) 0
Vomiting 5 (8) 0
Leukocytosis 4 (6) 0
Tachycardia 2 (3) 2 (5)
Urinary tract
infection
4 (6) 0
Hypokalemia 1 (2) 2 (5)
Cellulitis 0 2 (5)
IV ¼ intravenous; PCA ¼ patient-controlled analgesia.
n Values are given as n (%).
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with patients assigned to opioid-based IV PCA.
In our combined analysis of 6 IMPROVE studies of patients
undergoing laparoscopic colectomy, the use of liposome
bupivacaine-based multimodal analgesia for the management of
postsurgical pain was associated with a statistically signiﬁcant
improvement compared with IV opioid-based PCA in 2 of 3 copri-
mary outcome measures. The multimodal analgesia regimen
reduced mean postsurgical opioid consumption by 67% and
reduced median LOS by 1 day compared with a standard IV
opioid-based PCA analgesia regimen. Multimodal analgesia was
also associated with a nonstatistically signiﬁcant 14% reduction in
mean total hospitalization cost ($1784) compared with an IV
opioid PCA regimen. Although the observed reduction in hospital
costs was not statistically signiﬁcant, it was clinically meaningful
and suggests that improvements in the other 2 measures may have
mitigated the product cost of liposome bupivacaine. This is an
encouraging observation given the increased focus on evidence-
based medicine and comparative effectiveness research that takes
into account both patient outcomes and the treatment costs
associated with novel medical interventions.
Encouraging results were also observed with respect to secon-
dary outcome measures. Compared with IV opioid PCA, liposome
bupivacaine-based multimodal analgesia signiﬁcantly extendedTable IV
Summary of opioid-related adverse events (efﬁcacy population).*
Adverse event
IV opioid PCA
regimen
(n ¼ 56)
Liposome bupivacaine-based
multimodal regimen (n ¼ 26)
Patients with any opioid-
related adverse event
23 (41) 2 (8)†
Nausea 17 (30) 2 (8)‡
Pruritus 5 (9) 0
Urinary retention 4 (7) 0
Vomiting 4 (7) 0
Postoperative ileus 2 (4) 0
Somnolence 1 (2) 0
IV ¼ intravenous; PCA ¼ patient-controlled analgesia.
nValues are given as n (%).
†P ¼ 0.0019 for between-group comparison.
‡P ¼ 0.0261 for between-group comparison.the time to ﬁrst postsurgical opioid use, which is consistent with
the reduction in opioid consumption observed on the primary
outcome measure for the multimodal group and also signiﬁcantly
reduced the incidence of ORAEs overall (as well as nausea,
speciﬁcally). Although between-group differences in other secon-
dary measures did not reach statistical signiﬁcance, 65% of patients
in the multimodal analgesia group reported being “extremely
satisﬁed” with their postsurgical analgesia regimen, which sug-
gests this regimen was well accepted by most patients in this
treatment group.
Our results mirror those observed by Cohen20 in a similarly
designed single-center study of patients undergoing open colec-
tomy. In that study, a liposome bupivacaine-based multimodal
analgesia regimen was associated with signiﬁcant reductions in
opioid consumption, LOS, and hospitalization costs compared with
an IV opioid PCA regimen.20
We conducted these studies against a backdrop of an increasing
trend toward the use of accelerated or enhanced recovery path-
ways for patients undergoing colorectal surgical procedures.24–27
The reductions in opioid consumption and LOS observed in these
studies are encouraging in light of this trend, and suggest that
liposome bupivacaine-based multimodal analgesic regimens
may play a role in supporting continued efforts to improve and
shorten the recovery experience for patients undergoing colorectal
surgery.
Important limitations of this analysis include the open-label
design, small study populations, and the use of sequential cohorts
instead of randomization; it is possible that the latter may have
introduced some level of unanticipated variability in patient
populations that were enrolled. Also, the treatment effects that
can be speciﬁcally attributed to liposome bupivacaine in this study
are difﬁcult to quantify, because the multimodal analgesic regimen
was composed of several analgesic medications (ie, ketorolac,
acetaminophen, ibuprofen, and liposome bupivacaine), and these
were not evaluated separately.Conclusions
Our analysis showed that liposome bupivacaine-based multi-
modal analgesia signiﬁcantly reduced postsurgical opioid consump-
tion and hospital LOS, as well as the incidence of ORAEs, when
compared with conventional opioid-based IV PCA in patients
undergoing laparoscopic colectomy. Liposome bupivacaine-based
multimodal analgesia may be an important tool in improving
postsurgical outcomes associated with this procedure.Acknowledgments
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